Intratumoral immunotherapy with interferon-alpha and interleukin-2 in glioblastoma.
The combination of the cytokines interferon-alpha 2b and rIL-2, at doses of 10 x 10(6) IU and 9 x 10(6) IU, respectively, in a 1.5 cc solution, can be safely injected into cystic glioblastoma without any evidence of side effects or increase in surrounding tumoral oedema. Nevertheless, an immunotherapeutic protocol in ten glioblastoma patients with tumour growth, that consisted of one intralesional injection per week, over 4 weeks of this combination of cytokines, had no effect on tumour progression.
Vaquero
J
J
Department of Neurosurgery, Puerta de Hierro Clinic, Autonomous University, Madrid, Spain.
Martínez
R
R
D001932:Brain Neoplasms / Q000628:therapy*; D005260:Female; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D015552:Injections, Intralesional; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013238:Stereotaxic Techniques
D016898:Interferon-alpha; D007376:Interleukin-2